0
0
11/19/22 at 7:00am
Organization
Cancertherapyadvisor.com
Author
Stephan Cho
30 words
0
Comments
Recurrence of esthesioneuroblastoma with non-contiguous intracranial metastasis is possible 19 years after remission, a review suggests.
You are the first to view
https://www.cancertherapyadvisor.com/home/news/conference-coverage/society-for-neuro-oncology/sno-2022/intra-cranial-metastasis-esthesioneuroblastoma-brain-cancer-treatment-risk/
Create an account
or login to join the discussion